儿童及小鼠镰状细胞贫血中白蛋白尿的自然史与变异性
该自然史研究纳入355例≥5岁血红蛋白SS/SB0地中海贫血患者共1728次白蛋白/肌酐比值(ACR)测量,17%为持续性白蛋白尿、13%为间歇性;单次ACR≥100 mg/g与持续性白蛋白尿风险升高相关(OR 55.5,95%CI 12.3-527),重复测量变异大,小鼠模型呈现约20%的变异。
要点
- 355例HbSS/SB0患者中17%持续性、13%间歇性白蛋白尿
- 单次ACR≥100 mg/g与持续性白蛋白尿风险升高相关(OR 55.5)
- 持续性白蛋白尿患者中13%在10岁前出现异常ACR
核心结论
- 证据提示应制定重复ACR测量的标准,考虑在10岁前筛查ACR,并将ACR>100 mg/g作为进展的危险因素。
- 儿童及小鼠肾脏保护临床试验需考虑重复ACR测量的高变异性。
研究设计与样本
- 儿童白蛋白尿自然史研究,纳入355例≥5岁血红蛋白SS/SB0地中海贫血患者,共1728次稳态门诊ACR测量。
- 将参与者分为持续性、间歇性或无白蛋白尿,并在镰状细胞贫血小鼠模型中镜像研究白蛋白尿测量变异。
主要发现
- 355例参与者中17%为持续性白蛋白尿,13%为间歇性白蛋白尿。
- 持续性白蛋白尿参与者中13%在10岁前出现异常ACR。
- 单次ACR≥100 mg/g与持续性白蛋白尿的比值比为55.5(95%CI 12.3-527)。
- ACR≥100 mg/g者初次与下一次测量ACR中位数分别为175.8 mg/g(IQR 135-242)和117.3 mg/g(IQR 64-292)。
- 小鼠模型中人ACR变异被约20%的白蛋白尿变异所镜像。
关键数值与推荐
- 持续性白蛋白尿患病率17%,间歇性白蛋白尿13%(355例HbSS/SB0患者)。
- 单次ACR≥100 mg/g与持续性白蛋白尿的OR为55.5(95%CI 12.3-527)。
- 持续性白蛋白尿患者中13%在10岁前出现异常ACR。
- ACR≥100 mg/g者初次ACR中位数175.8 mg/g(IQR 135-242),下一次117.3 mg/g(IQR 64-292)。
- 小鼠模型白蛋白尿变异约20%。
临床怎么用
- 作者认为应采用重复ACR测量的标准。
- 作者建议考虑在10岁前进行ACR筛查。
- 作者建议将ACR>100 mg/g作为进展的危险因素。
- 作者认为儿童及小鼠肾脏保护临床试验需考虑重复ACR测量的高变异性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is critical to characterize the natural history of albuminuria in patients with sickle cell anemia (SCA); however, these data are currently lacking and affecting evidence-based guidelines. We performed a natural history study of the development of pediatric albuminuria. We identified participants with hemoglobin SS/SB0 thalassemia ≥5 years with albumin to creatinine ratio (ACR) measurements performed at a steady-state clinic visit. Participants were characterized as either persistent, intermittent, or never albuminuria. We determined the prevalence of persistent albuminuria, use of ACR ≥100 mg/g as a predictor, and variation in ACR measurements. We mirrored this study to determine the variation in albuminuria measurements in the SCA murine model. Among 355 participants with HbSS/SB0 thalassemia with 1728 ACR measurements, we identified 17% with persistent and 13% with intermittent albuminuria. Thirteen percent of participants with persistent albuminuria developed an abnormal ACR before 10 years of age. A single ACR measurement ≥100 mg/g was associated with 55.5 times (95% confidence interval, 12.3-527) higher odds of having persistent albuminuria. Among participants with ACR ≥100 mg/g, we identified significant variability in the results of repeated measurements. The median ACR at the initial and next measurements were 175.8 mg/g (interquartile range [IQR], 135-242) and 117.3 mg/g (IQR, 64-292). The human variability in ACR was mirrored by ∼20% variability in albuminuria in murine model. This evidence suggests adopting standards for repeating ACR measurements, consider screening for ACR before 10 years of age, and using an ACR >100 mg/g as a risk factor for progression. Pediatric and murine renoprotective clinical trials need to consider the high variability in repeated ACR measurements.
引用
- Kasztan M, Aban I, Baker K, et al. Natural history and variability in albuminuria in pediatric and murine sickle cell anemia. Blood Adv. 2023. PMID: 37428862. doi:10.1182/bloodadvances.2023010101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。